PE20241189A1 - Nuevos derivados de tiazolopirimidinona - Google Patents
Nuevos derivados de tiazolopirimidinonaInfo
- Publication number
- PE20241189A1 PE20241189A1 PE2023002576A PE2023002576A PE20241189A1 PE 20241189 A1 PE20241189 A1 PE 20241189A1 PE 2023002576 A PE2023002576 A PE 2023002576A PE 2023002576 A PE2023002576 A PE 2023002576A PE 20241189 A1 PE20241189 A1 PE 20241189A1
- Authority
- PE
- Peru
- Prior art keywords
- heterocycloalkyl
- cycloalkyl
- alkyl
- compound
- thiazolpyrimidinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se refiere a un compuesto de formula (I), a un proceso para la preparacion del compuesto, una composicion farmaceutica y metodo para el tratamiento o la profilaxis de una enfermedad neurodegenerativa, en particular la enfermedad de Huntington. De manera especifica hace referencia a un compuesto de formula (I) en el que R1 es H, alquilo, cicloalquilo, arilo, heteroarilo o heterocicloalquilo, en el que cada caso de cicloalquilo, arilo, heteroarilo y heterocicloalquilo esta opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes independientemente seleccionados de R4; R2 es H, cicloalquilo, alquenilo, entre otros; R3 es alquilo, hidrogeno, halogeno o haloalquilo; R4 es halogeno, alquilo, heterocicloalquilo, entre otros; y (i) A1 es -N-, A2 es -N- y A3 es -CH-; (ii) A1 es -N-, A2 es -C- y A3 es -O-; o (iii) A1 es -CH-, A2 es -C- y A3 es -O-; o una sal farmaceuticamente aceptable del mismo; siempre que 2-(4,7-diazaspiro[2.5]octan-7-il)-7-(2,8-dimetilimidazo[1,2-b]piridazin-6-il)tiazolo[3,2-a]pirimidin-5-ona; se excluya.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21163259 | 2021-03-17 | ||
| PCT/EP2022/056586 WO2022194801A1 (en) | 2021-03-17 | 2022-03-15 | New thiazolopyrimidinone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20241189A1 true PE20241189A1 (es) | 2024-06-03 |
Family
ID=74947249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002576A PE20241189A1 (es) | 2021-03-17 | 2022-03-15 | Nuevos derivados de tiazolopirimidinona |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240018163A1 (es) |
| EP (1) | EP4308576B1 (es) |
| JP (1) | JP2024514421A (es) |
| KR (1) | KR20230157367A (es) |
| CN (1) | CN116981674A (es) |
| AU (1) | AU2022240935A1 (es) |
| BR (1) | BR112023018466A2 (es) |
| CA (1) | CA3212341A1 (es) |
| CL (1) | CL2023002705A1 (es) |
| CO (1) | CO2023012574A2 (es) |
| CR (1) | CR20230437A (es) |
| IL (1) | IL305203A (es) |
| MX (1) | MX2023010719A (es) |
| PE (1) | PE20241189A1 (es) |
| TW (1) | TW202302604A (es) |
| WO (1) | WO2022194801A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230005210A (ko) * | 2020-04-08 | 2023-01-09 | 레믹스 테라퓨틱스 인크. | 스플라이싱을 조절하기 위한 화합물 및 방법 |
| WO2023064879A1 (en) * | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2812004B1 (en) | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| HRP20230637T1 (hr) | 2014-05-15 | 2023-09-29 | F. Hoffmann - La Roche Ag | Postupak za proizvodnju spojeva korisnih za liječenje spinalne mišićne atrofije |
| AU2018282154B2 (en) * | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111182898B (zh) * | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2020002711A (es) | 2017-09-22 | 2020-07-20 | Hoffmann La Roche | Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona. |
| WO2020005877A1 (en) * | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3814360B8 (en) * | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| KR20230005210A (ko) * | 2020-04-08 | 2023-01-09 | 레믹스 테라퓨틱스 인크. | 스플라이싱을 조절하기 위한 화합물 및 방법 |
-
2022
- 2022-03-15 JP JP2023556976A patent/JP2024514421A/ja active Pending
- 2022-03-15 CR CR20230437A patent/CR20230437A/es unknown
- 2022-03-15 WO PCT/EP2022/056586 patent/WO2022194801A1/en not_active Ceased
- 2022-03-15 EP EP22714821.0A patent/EP4308576B1/en active Active
- 2022-03-15 BR BR112023018466A patent/BR112023018466A2/pt not_active Application Discontinuation
- 2022-03-15 CN CN202280021604.7A patent/CN116981674A/zh active Pending
- 2022-03-15 KR KR1020237032218A patent/KR20230157367A/ko active Pending
- 2022-03-15 AU AU2022240935A patent/AU2022240935A1/en active Pending
- 2022-03-15 CA CA3212341A patent/CA3212341A1/en active Pending
- 2022-03-15 MX MX2023010719A patent/MX2023010719A/es unknown
- 2022-03-15 PE PE2023002576A patent/PE20241189A1/es unknown
- 2022-03-15 IL IL305203A patent/IL305203A/en unknown
- 2022-03-16 TW TW111109552A patent/TW202302604A/zh unknown
-
2023
- 2023-09-11 CL CL2023002705A patent/CL2023002705A1/es unknown
- 2023-09-15 US US18/468,378 patent/US20240018163A1/en active Pending
- 2023-09-22 CO CONC2023/0012574A patent/CO2023012574A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3212341A1 (en) | 2022-09-22 |
| CO2023012574A2 (es) | 2023-09-29 |
| EP4308576B1 (en) | 2025-04-23 |
| CN116981674A (zh) | 2023-10-31 |
| JP2024514421A (ja) | 2024-04-02 |
| KR20230157367A (ko) | 2023-11-16 |
| AU2022240935A1 (en) | 2023-08-24 |
| BR112023018466A2 (pt) | 2023-10-10 |
| TW202302604A (zh) | 2023-01-16 |
| EP4308576A1 (en) | 2024-01-24 |
| MX2023010719A (es) | 2023-09-20 |
| WO2022194801A1 (en) | 2022-09-22 |
| CR20230437A (es) | 2023-10-16 |
| CL2023002705A1 (es) | 2024-03-15 |
| EP4308576C0 (en) | 2025-04-23 |
| US20240018163A1 (en) | 2024-01-18 |
| IL305203A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241189A1 (es) | Nuevos derivados de tiazolopirimidinona | |
| PE20190475A1 (es) | Inhibidores de cdk2/4/6 | |
| RU2018136104A (ru) | СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1,2,4]ТРИАЗОЛО[1,5- c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ A2А АНТАГОНИСТОВ | |
| PE20170321A1 (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos | |
| AR061083A1 (es) | Derivados de cicloalquilaminoacidos y composiciones farmaceuticas que los contienen | |
| CO2018008799A2 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de jak | |
| PE20170003A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| BR112019027717A2 (pt) | métodos para tratar a doença de huntington | |
| PE20241762A1 (es) | Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias | |
| MA56649B1 (fr) | Dérivés 6,7-dihydro-5h-pyrido[2,3-c]pyridazine et composés similaires en tant qu'inhibiteurs de la protéine bcl-xl et agents pro-apoptotiques pour le traitement du cancer | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20170128A1 (es) | Compuestos para tratar atrofia muscular espinal | |
| JP2017524702A (ja) | ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用 | |
| CA2780190A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| RU2012119488A (ru) | Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором | |
| AR043434A1 (es) | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos | |
| ECSP10010506A (es) | Derivados de 1-heterociclilo-1,5-dihidro-pirazol [3,4-D] pirimidino-4-ona y su uso como inhibidores de PDE9A. | |
| PE20171342A1 (es) | Compuestos y su uso como inhibidores de bace | |
| PE20110922A1 (es) | DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1) | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| PE20120224A1 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| PE20080182A1 (es) | Derivados pirrolo-quinoxalinona como antibacterianos | |
| AR084412A1 (es) | Compuestos de piridina fusionados, utiles como inhibidores de caseina quinasa, y las composiciones farmaceuticas que los contienen | |
| PE20090944A1 (es) | PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT |